mol42
13 Dec 2017
bit of info albeit back in sept 17 - article by amrikGuest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic antibodies[link]
mol42
13 Dec 2017
Re: 3% shareholders 071217 Current significant shareholders are as followsIP Group plc – 24.79%Lombard Odier Asset Management – 10.77%Aviva 9.60%Ruffer LLP – 7.08%J O Hambro - 6.72%Baillie Gifford & Co Limited – 6.23%Fidelity - 5.94%NFU - 3.49%As at 7th December 2017 the company has 68,632,835 ordinary shares of 10p each in issue42.3% of the ordinary shares of the Company are not held in public handspreviously 280917IP Group plc – 24.79%Henderson Global Investors – 11.39%Aviva - 9.60%Ruffer LLP – 7.08%Baillie Gifford & Co Limited – 6.62%J O Hambro - 5.99%Fidelity - 5.94NFU - 3.49%As at 28th September 2017 the company has 68,397,933 ordinary shares of 10p each in issue.42.3% of the ordinary shares of the Company are not held in public hands.sortedmol
mol42
13 Dec 2017
Re: 3% shareholders 071217 Current significant shareholders are as follows IP Group plc – 24.79%
Lombard Odier Asset Management – 10.77%
Aviva 9.60%
Ruffer LLP – 7.08%
J O Hambro - 6.72%
Baillie Gifford & Co Limited – 6.23%
Fidelity - 5.94%
NFU - 3.49%As at 7th December 2017 the company has 68,632,835 ordinary shares of 10p each in issue42.3% of the ordinary shares of the Company are not held in public handspreviously 280917IP Group plc – 24.79%Henderson Global Investors – 11.39%Aviva - 9.60%Ruffer LLP – 7.08%Baillie Gifford & Co Limited – 6.62%J O Hambro - 5.99%Fidelity - 5.94NFU - 3.49%As at 28th September 2017 the company has 68,397,933 ordinary shares of 10p each in issue.42.3% of the ordinary shares of the Company are not held in public hands.apologies if any placeholders present on postingmol
TheDrewster
16 Nov 2017
Shareholder Update CEO, CFO & FinnCap analyst, plus just THREE PIs.Am I happy that I'm invested here. Yes.Do I believe in the technology. Yes.I have a target between 10 and 50 times the current market cap, so depending on how much extra cash is needed to get to those transformational commercial deals, still rates a good risk reward play for now.
mol42
24 Oct 2017
Re: AS shares investor meeting oops - lolslides[link]
mol42
24 Oct 2017
Re: AS shares investor meeting slides available[link] updated with other recent presentations as well[link]
mol42
24 Oct 2017
AS shares investor meeting video available now[link]
mol42
09 Oct 2017
AS 091017 elevator pitch today[link] by proactive investors apparently - never heard of it before[link] you will note AS in above link - not how i stumbled across it thoughand not sure why this cameo performance was deemed necessary in first placeanywayjust show a substantial growth in quantum of revenue in next six months and further indication of potential milestone payments and actual milestone paymentsmol
mol42
04 Oct 2017
Re: AS 041017 Yorkshire Post this afternoon[link]
mol42
04 Oct 2017
AS 041017 Interview[link]
mol42
28 Sep 2017
3% shareholders 280917 Current significant shareholders are as followsIP Group plc – 24.79%
Henderson Global Investors – 11.39%
Aviva - 9.60%
Ruffer LLP – 7.08%
Baillie Gifford & Co Limited – 6.62%
J O Hambro - 5.99%
Fidelity - 5.94%
NFU - 3.49%As at 28th September 2017 the company has 68,397,933 ordinary shares of 10p each in issue.42.3% of the ordinary shares of the Company are not held in public hands.previously 250517IP Group plc – 24.8%Henderson Global Investors – 11.5%Aviva -9.6%Baillie Gifford & Co Limited – 7.2%Ruffer LLP – 7.1%Fidelity - 5.8%J O Hambro - 5.7%NFU - 3.5%As at 25th May 2017 the company has 68,392,588 ordinary shares of 10p each in issue.42.3% of the ordinary shares of the Company are not held in public hands.mol
mol42
24 Sep 2017
Re: Moderna moderna update 140917[link] extract ( though worth a read overall re dev pipeline)Maintained strong cash position: Moderna has maintained a strong cash position in 2017. As of June 30, 2017, the company had $1.098 billion in cash, as compared to $1.307 billion in cash as of December 31, 2016. This affords Moderna several years of runway to support its continued growth and pipeline acceleration.they are becoming more and more open this year - presumably with a future public fund raise in mindas we know from our trading update ahead of annual resultsPartnership with Moderna expanded to include more drug targetsalbeit it is now over two years since[link] payment into our coffers would be more than welcome!bw allmolmol
mol42
24 Sep 2017
bit of info another significant investor though not listed (at least as at 300617 - though methinks continues to date)[link] 53mol
mol42
22 Sep 2017
Re: Research Paper 210917 another link - which hopefully works (other one does with a bit of effort!)[link]
mol42
22 Sep 2017
Research Paper 210917 [link] on website as well - however don't ask me for any further explanation - lolAvacta commentThese exciting findings by David Komander’s group using Affimer reagents open the door to the investigation of both atypical K6 and K33 ubiquitin linkages across the biological field, which has proven previously impossible in this way, and holds potential impact for drug discovery within this developing field.mol
